![Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma](https://www.frontiersin.org/files/Articles/454940/fonc-09-00537-HTML/image_m/fonc-09-00537-g001.jpg)
Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
![Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy](https://www.cell.com/cms/attachment/5bce48f4-5d8b-4f4a-bcfb-b55f0b7a9a28/gr1_lrg.jpg)
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy
![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/244642bf-33f8-469a-a9ca-0d7de2d9cdb6/gr1_lrg.gif)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
![Is immunotherapy in the future of therapeutic management of sarcomas? | Journal of Translational Medicine | Full Text Is immunotherapy in the future of therapeutic management of sarcomas? | Journal of Translational Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12967-021-02829-y/MediaObjects/12967_2021_2829_Fig3_HTML.png)
Is immunotherapy in the future of therapeutic management of sarcomas? | Journal of Translational Medicine | Full Text
![Frontiers | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review Frontiers | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review](https://www.frontiersin.org/files/Articles/1044707/fonc-12-1044707-HTML/image_m/fonc-12-1044707-g001.jpg)
Frontiers | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review
![Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer](http://static1.squarespace.com/static/5de28c8008114a27bbd10042/5f48257d18e160050b29d7e5/61ba7bc5dc340c374dc4e6df/1639674937976/851CBEAB-1913-4CC8-863C-BF92717C2FAD.jpeg?format=1500w)